Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of <named-content content-type="genus-species">Mycobacterium tuberculosis</named-content>

Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of <named-content content-type="genus-species">Mycobacterium tuberculosis</named-content>

ABSTRACT New drugs are needed to control the current tuberculosis (TB) pandemic caused by infection with Mycobacterium tuberculosis. We report here on our work with AX-35, an arylvinylpiperazine amide, and four related analogs, which are potent antitubercular agents in vitro. All five compounds show...

Full description

Saved in:
Bibliographic Details
Main Authors: Caroline S. Foo, Andréanne Lupien, Maryline Kienle, Anthony Vocat, Andrej Benjak, Raphael Sommer, Dirk A. Lamprecht, Adrie J. C. Steyn, Kevin Pethe, Jérémie Piton, Karl-Heinz Altmann, Stewart T. Cole
Format: article
Language:EN
Published: American Society for Microbiology 2018
Subjects:
QcrB inhibitor
cytochrome bc1 oxidase
cytochrome bd oxidase
mycobacterial diseases
mycobacterial respiration
tuberculosis
Microbiology
QR1-502
Online Access:https://doaj.org/article/adb9ac67e2c14c6b855d0f2b8719a48c
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items